Back to About

Company News

Stay updated with the latest news, announcements, and developments from AbOliGo as we advance antibody-oligonucleotide conjugate technology.

Funding

AbOliGo Closes Oversubscribed Round to Accelerate Multiomic Research Tools and Appoints Proven Life Sciences Board

AbOliGo announces successful close of oversubscribed seed funding round and formation of expert Board of Directors to accelerate AOC manufacturing and commercial growth.

By Brian Carpenter
Read full article